As previously reported, Wells Fargo upgraded Globus Medical to Overweight from Equal Weight with a price target of $78, up from $60. The firm notes that when it downgraded the stock, Wells expected a challenging integration process as a result of vastly different cultures between Globus Medical and NuVasive. In addition, the firm expected sales force and customer disruption given a complicated integration process. However, management has handled the integration process far better than Wells expected and Globus Medical has exceeded Street expectations over the past three quarters.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- GMED Upcoming Earnings Report: What to Expect?
- Globus Medical Receives FDA 510(k) Clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee System
- Globus Medical receives FDA 510k clearance for ExcelsiusFlex, ACTIFY
- Globus Medical price target raised to $78 from $63 at Truist
- Globus Medical price target raised to $71 from $67 at Morgan Stanley